NCAM1 and cancer: Regarding the characteristic co-expression of CD39 and CD73 on regulatory CD56+CD16− NK cells, we and others recently found in line with our data, that circulating or tissue-derived CD56+ NK cells from cancer patients highly express CD39 and CD73 and thereby acting immunosuppressive via extracellular adenosine generation [27].